In this second-part of a two-part interview piece, Koen Cobbaert, senior manager, quality, standards and regulations, at Royal Philips looks in more detail at the impossible situation that notified bodies could find themselves in due to the new AI Act, at how it will impact IVDs in particular, and at the very important, but potentially compromised, issue of standards.
Koen
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?